Skip to content
ETEN
Findshops
Science & Health

Medical cannabis and insomnia: a two-year study follows positive findings in 61 patients

Illustrative photograph of a bedroom accompanying insomnia research

Updated in November 2026. Patients with insomnia in the UK Medical Cannabis Registry have reported improved sleep. These observational findings do not establish that cannabis treatment caused the improvement. A 2024 analysis of 61 patients found better reported sleep quality, less anxiety and improved quality of life after cannabis-based medicines were prescribed. A longer follow-up study published in 2026 also reported positive changes over two years.

The first study: sleep quality improved in the early months

Bedroom illustrating sleep research, not a participant’s home
Photograph illustrating sleep research, not the home of a study participant. Photo: Charlotte May / Pexels.

A study published in Brain and Behavior in February 2024 analyzed 61 patients prescribed cannabis-based medicinal products for insomnia in the United Kingdom. Researchers used patients’ own ratings of sleep quality, anxiety and health-related quality of life.

Sleep scores improved significantly at one, three and six months. Anxiety and general quality-of-life scores also improved at those time points. These findings matter for patients whose insomnia can substantially affect daily functioning.

Prescription information was available for 57 patients: 24 received dried cannabis flower for vaporization, 16 received oils and 17 received both. The study therefore concerned prescribed medicines, rather than casual use of unregulated products.

Adverse events were reported by a minority of patients

Adverse events were recorded in eight of the 61 patients, or 13.1%. There were 28 events in total, with none reported as life-threatening or causing persistent disability. The number of people reporting events should therefore be distinguished from the total number of events.

Although the findings were positive, the study had no placebo or usual-care comparison group. Fewer patients also completed assessments at six months than at baseline. These limitations affect how broadly the results can be applied.

The 2026 study: improved sleep ratings over two years

A later prospective observational study using the same UK registry included 211 patients with insomnia and followed outcomes for up to 24 months. Mean self-reported sleep quality scores improved from 2.46 to 5.14, a difference of 2.68 points.

The largest improvements were observed among patients with the poorest sleep at baseline. Seventeen patients, or 8.06% of the sample, reported adverse events. The findings justify further research, but without a control group they cannot establish that medical cannabis caused the improvement.

Why does this matter for cannabis research?

Insomnia treatments do not work equally well for everyone, and some patients seek additional options when existing approaches are insufficient. These registry studies support closer investigation of which patients, cannabinoid preparations and doses might be associated with improved sleep.

Both studies were observational, rather than randomized placebo-controlled trials. Expectations, other treatments and selection bias cannot be excluded. Patients’ repeated reports of improved sleep are nevertheless a useful starting point for further clinical research.

Primary sources: Vivek and colleagues, UK Medical Cannabis Registry: Assessment of clinical outcomes in patients with insomnia, Brain and Behavior (2024), DOI 10.1002/brb3.3410; and UK Medical Cannabis Registry: A Two-Year Prospective Observational Cohort Study of Clinical Outcomes in Insomnia (2026).

Sources

Illustrative photograph: Charlotte May / Pexels, Pexels License. Cropped to 16:9.

Share article
REKLAAMIPIND
Your ad here

Advertising space available.

Get in touch ↗

Lisa kommentaar

Your email address will not be published. Required fields are marked *